When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
KTOV - Dosing underway in Kitov Pharma's NT219 study in advanced cancer patients
Kitov Pharma Ltd.
Kitov Pharma (NASDAQ:KTOV)announces that the first patient has been dosed in the Phase 1/2 clinical trial evaluating NT219 as monotherapy treatment of advanced solid tumors, as well as in combination with cetuximab, for the treatment of recurrent and/or metastatic solid tumors and head and neck cancer or colorectal adenocarcinoma.
More news on: Kitov Pharma Ltd, Healthcare stocks news,